EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer

Jan Taprogge iD, Iain Murray, Hannah Sharman, Paul Gape, Francesca Leek, Carla Abreu, Lenka Vávrová, Kate Newbold, Kee H Wong, Markus Luster, Frederik A Verburg, Tino Schurrat und 8 weitere

European Thyroid Journal · 2025

DOI: 10.1530/etj-25-0097 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Jan Taprogge und 19 weiteren Autor:innen. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Thyroglobulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Euratom Research and Training Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Serum thyroglobulin measurements are used in the long-term management of patients with differentiated thyroid cancer following thyroidectomy and radioiodine therapy. The use of predictive biomarkers, such as post-operative stimulated thyroglobulin levels and absorbed dose, may help to identify patients at risk of disease recurrence or an unsuccessful initial treatment.

Methods

Differentiated thyroid cancer patients treated with 1.1 or 3.7 GBq of radioiodine using recombinant human thyrotropin stimulation or thyroid hormone withdrawal were recruited into observational clinical studies in France, Germany and the UK with aligned study endpoints (MEDIRAD). The maximum absorbed dose to the thyroid remnant was determined and compared to post-operative stimulated thyroglobulin with respect to its ability to predict ablation success. Radioiodine therapy success was defined as unstimulated or stimulated thyroglobulin level of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsThyroglobulinHumansMaleFemaleMiddle AgedAdultProspective StudiesTreatment OutcomeAgedThyroidectomyThyrotropinGermany

Stichwörter der Autor:innen

differentiated thyroid cancdosimetrymulti-centre trialradioiodine

Substanzen

Iodine RadioisotopesThyroglobulinThyrotropin

Autor:innen und Institutionen

ORCID-Profile: Jan Taprogge, Glenn Flux

Förderung

  • Euratom Research and Training Programme

Zitieren

APA

Taprogge, J., Murray, I., Sharman, H., Gape, P., Leek, F., Abreu, C., Vávrová, L., Newbold, K., Wong, K. H., Luster, M., Verburg, F. A., Schurrat, T., Vija, L., Courbon, F., Vallot, D., Bardiès, M., Schumann, S., Eberlein, U., Lassmann, M., & Flux, G. (2025). Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-25-0097

Vancouver

Taprogge J, Murray I, Sharman H, Gape P, Leek F, Abreu C, et al. Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. European Thyroid Journal. 2025. doi:10.1530/etj-25-0097

BibTeX
@article{Taprogge2025,
  author = {Taprogge, Jan and Murray, Iain and Sharman, Hannah and Gape, Paul and Leek, Francesca and Abreu, Carla and Vávrová, Lenka and Newbold, Kate and Wong, Kee H and Luster, Markus and Verburg, Frederik A and Schurrat, Tino and Vija, Lavinia and Courbon, Frédéric and Vallot, Delphine and Bardiès, Manuel and Schumann, Sarah and Eberlein, Uta and Lassmann, Michael and Flux, Glenn},
  title = {Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer},
  journal = {European Thyroid Journal},
  year = {2025},
  doi = {10.1530/etj-25-0097}
}
Kostenlos starten →